Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises ~~an~~ a first annexin protein coupled to ~~at least one additional protein~~ a second annexin protein.

2-5. (cancelled)

6. (currently amended) The method of claim 1, wherein said first annexin protein is ~~an~~ a first annexin V protein.

7. (currently amended) The method of claim 6, wherein said first annexin V protein comprises an amino acid sequence selected from the group consisting of:
   a) SEQ ID NO:3; and
   b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3.

8. (currently amended) The method of claim 6, wherein said ~~additional~~ second annexin protein is ~~an additional~~ a second annexin V protein.

9. (currently amended) The method of claim 8, wherein said ~~additional~~ second annexin V protein comprises an amino acid sequence selected from the group consisting of:
   a) SEQ ID NO:3; and

b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3.

10. (currently amended) The method of claim 8, wherein said ~~isolated~~ modified annexin protein comprises an amino acid sequence selected from the group consisting of:
    a) SEQ ID NO:6; and
    b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:6.

11. (withdrawn) A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises an annexin protein coupled to polyethylene glycol.

12. (withdrawn) The method of claim 11, wherein said polyethylene glycol has a molecular weight of at least 10 kDa.

13. (withdrawn) The method of claim 11, wherein each modified annexin protein comprises at least two polyethylene glycol chains.

14. (withdrawn) The method of claim 1, wherein said annexin protein is an annexin V protein

15. (withdrawn) The method of claim 14, wherein said annexin V protein comprises an amino acid sequence selected from the group consisting of:
    a) an amino acid sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:6; and
    b) an amino acid sequence selected from the group consisting of an amino acid sequence having at least 95% sequence identity to an amino acid sequence of a).

16. (new) The method of claim 1, wherein said first annexin protein is human annexin protein.

17. (new) The method of claim 16, wherein said first annexin protein is coupled to said second annexin protein by a protein linker.

18. (new) The method of claim 16, wherein said second annexin protein is human annexin protein.

19. (new) The method of claim 18, wherein said first annexin protein is coupled to said second annexin protein by a protein linker.

20. (new) A method for treating sickle-cell disease in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a modified annexin protein, wherein said modified annexin protein comprises an annexin V protein coupled to at least one additional annexin V protein, wherein said isolated modified annexin protein comprises an amino acid sequence selected from the group consisting of:

a) SEQ ID NO:6; and

b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO:6.